Previous close | 23.71 |
Open | 23.71 |
Bid | 25.20 |
Ask | 26.05 |
Strike | 40.00 |
Expiry date | 2025-01-17 |
Day's range | 23.71 - 23.71 |
Contract range | N/A |
Volume | |
Open interest | 18 |
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials.The DSMB Recommended the Phase 3 Trials of Simufilam Continue as Planned, Without Modification AUSTIN, Texas, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced a positive interim safety review of simufilam in on-going Phase 3 clinical trials in
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.Results corroborate prior research from other academic researchers.These data once again confirm the biological activity of simufilam. AUSTIN, Texas, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the publication of new research that confirms the biological activity of simufilam. Simuf
AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present at the following investor conferences. Event:Morgan Stanley - 21stAnnual Global Healthcare ConferenceFormat:Fireside chat with Remi Barbier, President & CEODate:Monday, September 11, 2023Where:New York City Event:H.C. Wainwright - 25thAnnual Global Investment ConferenceForma